Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 8 of 8 for “"sPD-L1"”.

  1. Cirkuliuojančių prostatos vėžio imuninių veiksnių prognostinis vaidmuo /

    … one of the most common malignancies worldwide. sPD-1 and sPD-L1 molecules are poorly characterised in prostate cancer, but these molecules may provide new insights into disease progression and prognosis. The main aim of this study was to evaluate the prognostic value of circulating sPD-1, sPD-L1 …

    vilnius Repository record for Cirkuliuojančių prostatos vėžio imuninių veiksnių prognostinis vaidmuo / (opens in a new tab)

  2. Κυτταροκίνες και καρκίνος ενδομητρίου

    … therapeutic options are limited. The PD-1/PD-L1 axis has revolutionized immunotherapy and represents an important therapeutic target in advanced-stage lung cancer. However, there are insufficient data on whether these positive outcomes also apply to endometrial cancer, and the prognostic value …

    greece Repository record for Κυτταροκίνες και καρκίνος ενδομητρίου (opens in a new tab)

  3. INSIGHTS ON THE CROSSTALK BETWEEN THE IMMUNE SYSTEMAND CANCER: IMMUNE CHECKPOINT MOLECULES AND LYMPHOIDPOPULATIONS ASSESSMENT IN CANINE ROUND CELL TUMORS

    … prognostic role of programmed death-ligand 1 (PD-L1) in canine lymphoma, (2) the expression and prognostic role of CD47 in canine leukemias, and (3) the characterization of lymphocyte populations in peripheral blood and sentinel lymph nodes (SLNs) of dogs with mast cell tumors (MCTs). Regarding …

    milano Repository record for INSIGHTS ON THE CROSSTALK BETWEEN THE IMMUNE SYSTEMAND CANCER: IMMUNE CHECKPOINT MOLECULES AND LYMPHOIDPOPULATIONS ASSESSMENT IN CANINE ROUND CELL TUMORS (opens in a new tab) Embargoed

  4. Investigating biomarkers of response to anti-PD1 therapy in Hepatocellular Carcinoma

    … differences in soluble (s)BTLA, sCD27, sCD28, sPD-L1 at baseline between responders and non-responders in 240mg Nivolumab treated patients and differences in sMICB levels at baseline between R and NR in uninfected HCC patients. Longitudinally, differences in sCR concentration are observed in …

    kings Repository record for Investigating biomarkers of response to anti-PD1 therapy in Hepatocellular Carcinoma (opens in a new tab) Embargoed until 2028-06-01

  5. Lokalaus priešvėžinio gydymo modeliavimas panaudojant in vitro sistemą, sudarytą iš prostatos vėžio ląstelių DU-145 ir anti-PD-L1 imunomoduliatoriaus atezolizumabo /

    Atezolizumab is an anti-PD-L1 monoclonal antibody which targets immunosuppressive PD 1 and PD-L1 axis used by cancer cells to avoid the host immune system and is approved for treatment of several types of cancer. Despite its efficacy in some types of cancer, atezolizumab monotherapy shows limited …

    vilnius Repository record for Lokalaus priešvėžinio gydymo modeliavimas panaudojant in vitro sistemą, sudarytą iš prostatos vėžio ląstelių DU-145 ir anti-PD-L1 imunomoduliatoriaus atezolizumabo / (opens in a new tab)